Credit Suisse analyst Alethia Young upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from Neutral to Outperform with a price target of $165, marking a 32.6% increase from current levels.

The analyst took on this rating because she feels that several of Alexion’s pipeline drugs offer too much upside to ignore. Young notes that she lowered her price target due to several changes Alexion has to implement in addition to a decline in her long-term estimates for Kanuma, Alexion’s treatment for lysosomal acid lipase deficiency.

According to TipRanks, Young has a success rate of 47% with an average loss of 7.2% per recommendation.